DNA methylation changes induced by prenatal toxic metal exposure: An overview of epidemiological evidence

Alexander Vaiserman1 and Oleh Lushchak2,3,*

1Laboratory of Epigenetics, D.F. Chebotarev Institute of Gerontology, NAMS, 67 Vysokogorska str., Kyiv 04114, Ukraine, 2Department of Biochemistry and Biotechnology, Vasyl Stefanyk Precarpathian National University, 57 Shevchenka str., Ivano-Frankivsk 76018, Ukraine, 3Research and Development University, 13A Shota Rustaveli str., Ivano-Frankivsk 76000, Ukraine

*Correspondence address. Department of Biochemistry and Biotechnology, Vasyl Stefanyk Precarpathian National University, 57 Shevchenka str., Ivano-Frankivsk 76000, Ukraine, Tel/Fax: +38 0342 71 46 83; E-mail: oleh.lushchak@pnu.edu.ua

Abstract

Accumulating evidence suggests that exposure to unfavorable conditions early in life can substantially contribute to the risk of chronic disorders later in life (‘developmental programming’ phenomenon). The mechanistic basis for this phenomenon remains poorly understood so far, although epigenetic mechanisms such as DNA methylation, histone modifications and microRNA-mediated gene regulation apparently play a crucial role. The key role of epigenetic modifications triggered by unfavorable environmental cues during sensitive developmental periods in linking adverse early-life events to later-life health outcomes is evident from a large body of studies, including methylome-wide association studies and research of candidate genes. Toxic metals (TMs), such as heavy metals, including lead, chromium, cadmium, arsenic, mercury, etc., are among environmental contaminants currently most significantly impacting human health status. Since TMs can cross the placental barrier and accumulate in fetal tissues, exposure to high doses of these xenobiotics early in development is considered to be among important factors contributing to the developmental programming of adult-life diseases in modern societies. In this mini-review, we summarize epidemiological findings indicating that prenatal TM exposure can induce epigenetic dysregulation, thereby potentially affecting adult health outcomes.

Key words: toxic metals; prenatal exposure; epigenetics; DNA methylation; developmental programming; chronic disease

Introduction

Currently, there is a trend toward a rise in the prevalence of chronic non-communicable disorders (NCDs) worldwide. This is because the world’s population is rapidly aging, and burden of age-related disorders constitutes a major public health problem globally [1]. Adult-life lifestyle factors (sedentary behavior, westernized dietary patterns, etc.) obviously play a major role in the etiology of NCDs. However, accumulating evidence suggests that exposure to adverse environmental factors early in life can also substantially contribute to the pathogenesis of NCDs. To explain this phenomenon, the Developmental Origins of Health and Disease (DOHaD) concept has been postulated [2]. According to this concept, adverse environmental cues early in development may reprogram an individual for immediate adaptation to pre- and/or neonatal conditions. Such an adaptive strategy, however, can result in an increased risk of pathological conditions during adulthood, including type 2 diabetes (T2D), cardiovascular (CVD) and neurodegenerative disorders, as well as cancers [2]. The mechanistic basis for the phenomenon of ‘developmental programming’ of adult-life NCDs remains poorly understood so far, although epigenetic mechanisms such as DNA methylation, histone modifications and microRNA-mediated gene regulation apparently play a crucial role. In mammals, epigenome (a complex profile of epigenetic marks across the entire genome) has been found to be especially susceptible to adverse environmental conditions during gametogenesis and embryogenesis [3]. This is because epigenome undergoes the most significant modification during these stages of development. Once established, epigenetic profiles are stable and are transmitted into subsequent generations of somatic cells and, in some cases, into germ cells [4]. On the stage of maturation of germ cells, a wave of the genome-wide DNA demethylation takes place followed by remethylation before fertilization. One more wave of DNA demethylation takes place after fertilization in early human embryogenesis, and previously erased methylation patterns are re-established after embryo implantation [3]. This process of demethylation and remethylation during a post-fertilization period is believed to play a central role in the removal of epigenetic marks acquired by the previous generation.

In humans, the window of plasticity is known to extend from pre-conception until early childhood (‘First 1000 days’ concept) [5]. Epigenetic modifications triggered by unfavorable environmental cues during this sensitive developmental period may persist...
through many cell divisions and cause various pathological conditions later in life [5]. The key role of epigenetic modifications in linking adverse early-life events to later-life health outcomes is evident from a large body of methylome-wide association studies (MWAS) and studies of candidate genes that were performed during the last years [6].

In the past, famine-caused starvation and infections were the environmental factors most strongly affecting processes involved in early-life epigenetic reprogramming. Currently, due to industrial, traffic and agrochemical pollutions, exposure to xenobiotics (chemical substances foreign to biological systems, including humans) has more and more come to the fore. Toxic metals (TMs), such as heavy metals, are among environmental contaminants essentially influencing the health status of people [7, 8].

Exposure to TMs early in development is considered to be among important factors contributing to the developmental programming of adult-life diseases in modern societies [9]. The effects of TMs on epigenetic processes have been demonstrated in a large body of experimental in vitro and in vivo studies (for reviews, see refs. [10, 11]). They were found to be able to directly affect gene expression by binding particular metal response elements to target gene promoters [12]. More specifically, nickel can bind to chromatin, thereby causing its condensation, and chromium may crosslink chromatin-associated proteins to DNA [13]. Moreover, cadmium was shown to be able to promote global DNA hypermethylation by either stimulating activity of DNA methyltransferase (DNMT) or inducing its gene expression [14], and arsenite may deplete the main cellular methyl donor, S-adenosyl methionine, thereby causing DNA hypomethylation [15]. In addition, TMs may affect epigenetic pathways indirectly by inducing oxidative stress or disrupting cell metabolism [11].

The purpose of this mini-review was to summarize findings from epidemiological studies, indicating that prenatal TM exposure can induce epigenetic dysregulation at the DNA methylation level, thereby potentially affecting adult health outcomes. Since effects of developmental exposure to TMs on epigenetic mechanisms other than DNA methylation (such as histone modifications and regulation by non-coding RNAs) have not yet been comprehensively investigated in epidemiological studies, we will not discuss them here.

### Toxic Metals and Human Health

Environmental pollution by TMs such as lead (Pb), chromium (Cr), cadmium (Cd), arsenic (As) and mercury (Hg) is currently a matter of high concern because of their adverse effects on human health, which is increasingly becoming a challenge for health-care systems globally [16]. These inorganic pollutants enter the environment and contaminate the soil and groundwater owing to rapidly growing metal and agricultural industries and also pesticide and fertilizer production [7]. Although all TMs are naturally occurring elements, long-term intake of large amounts of these metals and their compounds can result in health hazards. Mechanistically, these deleterious effects can be likely mediated by inducing oxidative/nitrosative stresses following the TM exposure. These stresses may result in damage to vital biological macromolecules, such as lipids, proteins and DNA, as well as in disrupting essential signaling pathways, which in turn can contribute to the pathogenesis of human disorders [16]. Indeed, binding of TMs to DNA and nuclear proteins has been shown to be a primary cause of oxidative deterioration of vital biomolecules. Moreover, TMs may lead to disrupted integrity of important cellular processes due to displacement of certain essential metals from their respective sites [16]. The heavy metal–induced toxicity may lead to a decrease of energy levels and impaired functioning of the kidney, liver, brain, lungs and other vital organs [17]. As a result, these processes can initiate physical, muscular and neurological degenerative changes, thereby promoting the onset of diseases such as muscular dystrophy, Parkinson’s disease, Alzheimer’s disease, multiple sclerosis and cancer [7, 17].

From a DOHaD perspective, an important point is that TMs can cross the placental barrier, adversely affect placental functions and accumulate in fetal tissues. The placenta is known to act as a barrier that protects the growing fetus from external threats, including the potentially harmful chemical agents. The placental barrier is, however, not fully impenetrable. Indeed, relatively high concentrations of TMs have been detected in placental tissues, as well as in amniotic fluid and umbilical cord blood [18]. Evidence is also obtained that in utero exposures to lead and mercury pose a threat to health, particularly to the developing brain, while prenatal exposures to lead and cadmium are associated with both reduced birth size and birth weight [19]. Metal-specific placental transfer and impairment of placental functions were proposed to explain observed epidemiological associations between the prenatal exposure to TMs and the subsequent risk for developmental, endocrine and neurological disorders [18, 19].

There is compelling evidence that prenatal exposure to high doses of TMs is associated with adverse health outcomes in adulthood [7, 16, 17]. Recent findings indicate that these effects can be mediated by epigenetic modifications persisting throughout the life of affected offspring [20]. In the subsequent section, evidence from epidemiological studies is provided that epigenetic mechanisms may contribute to the link between prenatal exposure to TMs and adult health outcomes.

### Epigenetics as a Mediator between Prenatal Heavy Metal Exposures and Adult Health

#### Cadmium

Cadmium is a toxic, non-essential metal causing adverse health outcomes such as renal toxicity, cardiovascular disease and cancer [21]. These health outcomes have been well established in adults, although some research findings indicate that developmental exposures to cadmium may result in an increased risk of developing chronic diseases later in life. Several research findings suggest that long-lasting adverse health consequences of prenatal cadmium exposure may be mediated by epigenetic mechanisms. Sex-specific association between in utero exposure to cadmium and adult cord blood DNA methylation levels has been reported [22]. In girls, such methylation changes have been observed primarily in genes responsible for organ development and also for the bone morphology and mineralization, whereas in boys, these changes have been shown mainly in genes related to cell death due to apoptosis (for more details, see Table 1). In another MWAS conducted in leukocytes from mother–baby pairs exposed to cadmium during pregnancy, distortions in DNA methylation levels were observed primarily in genes implicated in processes of apoptosis and transcriptional regulation [23]. Evidence was also provided that cadmium-triggered developmental toxicity can be associated with disrupted expression patterns of certain imprinted placental genes that exhibit monoallelic expressions based on the parent of origin. More specifically, exposure to higher cadmium concentrations in utero was related to higher levels of expression of the distal-less homeobox 5 (DLX5) gene and lower levels of expression of the imprinted maternally expressed transcript (H19) and neclin, MAGE family member (NDN) gene [24]. Maternal cadmium...
Table 1: summary of epigenetic modifications caused by prenatal exposure to heavy metals

| TM          | Country                  | Age at detection                      | Tissue/cells                                      | Gene/element | Epigenetic outcome                        | Ref. |
|-------------|--------------------------|---------------------------------------|--------------------------------------------------|--------------|------------------------------------------|------|
| Cadmium     | Bangladesh (n = 127)     | Mother–child pairs; children at 4.5 years of age | Mothers: blood; Children: urine                  | MWAS         | Differential DNA methylation              | [22] |
|             | USA (n = 17)             | Mother–newborn pairs                  | Venous maternal blood; newborn cord blood         | DLX5, H19, NDN | High expression                           | [23] |
|             | USA: New Hampshire, Rhode Island (n = 211) | At birth                             | Placenta                                          |              | Low expression                            | [24] |
| Arsenic     | Bangladesh (n = 127)     | At birth                              | Mononuclear cells from cord blood                 | LINE-2, p16, p53, LUMA | Positive associations of methylation in males and inverse in females | [29] |
|             | USA (n = 134)            | At birth                              | White cord blood cells                            | LINE-2, p16, Alu, LINE-1, LUMA | Higher methylation levels                  | [30] |
|             | Bangladesh (n = 113)     | Mother–newborn pairs                  | Maternal and cord blood samples                   | H19, NDN    | Low expression                            | [25] |
|             | Bangladesh (n = 101)     | Mother–newborn pairs                  | Cord blood                                        | PEG3        | Lowered DMR methylation in female offspring | [25] |
|             | Taiwan (n = 299)         | Mother–newborn pairs                  | Cord blood                                        | MWAS        | Altered expression                        | [31] |
|             | Thailand (n = 32)        | At birth                              | Cord blood                                        | CXL1, DUSP1, IER2, EGR-1, JUNB, MIRN21, OSM, PTGS2, SFR55, SOC3, RNF149 | ~60% of identified CpGs positively associated with arsenic exposure | [32] |
|             |             |                                       |                                                  |              | Higher expression in girls                | [34] |
|             |             |                                       |                                                  |              | Changes in DNA methylation and messenger RNA expression | [35] |
|             | Belgium (n = 183)        | Mother–newborn pairs                  | Cord blood                                        | sFLT1       | Increased promoter methylation            | [36] |
|             | Mexico (n = 38)          | Mother–newborn pairs                  | Cord blood leukocytes                              | 16 genes    | Differentially methylated regions         | [37] |
|             | Thailand (n = 71)        | Mother–newborn pairs                  | Cord blood lymphocytes                             | pS3         | Decreased methylation                     | [38] |
|             | Bangladesh (n = 551)     | Mother–child pairs; 9-year-old children | Maternal and child urine                          | IGFBP3      | Differentially hydroxymethylated regions | [39] |
|             | Mexico (n = 103)         | Neonate                               | Cord blood                                        | Alu, LINE-1, 5-hmC | Differentially methylated CpG sites | [40] |
|             | Mexico (n = 48)          | Mother–child pairs                    | Umbilical cord blood leukocytes                   | 15 gene pathways | Differentially methylated regions | [41] |
|             | Mexico (n = 89)          | Mother–child pairs                    | Umbilical cord blood leukocytes                   |              |                                 |      |
| Lead        | USA (n = 268)            | At birth (n = 268); mid-childhood (n = 240) | Cord blood Venous blood                           | DNHD1, CLEC11A | Differentially methylated regions         | [42] |
| Mercury     | USA (n = 321)            | At birth (n = 321); early childhood (n = 75); mid-childhood (n = 291) | Cord blood Venous blood                           | MWAS        | Differentially Methylated regions         | [44] |
|             | USA (n = 138)            | Mother–newborn pairs                  | Cord blood                                        | MWAS        | Lowered regional DNA methylation; associated changes of expression at PON1 gene | [45] |

(continued)
exposure during early pregnancy was also associated with low birth weight and significantly lowered methylation level in the differentially methylated region (DMR) of the imprinted paternally expressed gene 3 (PEG3) in female offspring [25].

**Arsenic**

Arsenic is a potent toxicant and carcinogen. More than 100 million persons are currently exposed to high concentrations of this environmental pollutant, mostly via drinking water and industrial emissions [26]. Epidemiological studies conducted in regions with higher levels of arsenic in drinking water, such as several areas in Bangladesh and Chile, are indicative of an association between prenatal exposure to arsenic and risk for chronic disorders in adult life [26].

Epigenetic effects of prenatal exposure to arsenic are most thoroughly investigated among all TMs so far. Maternal arsenic levels early in gestation were associated with genome-wide methylation levels in cord blood of neonates, these effects were found to be more pronounced in boys than in girls [27]. Much stronger associations have been shown for arsenic exposure during early relative to late gestation. In the pathway analysis performed, overrepresentation of cancer-associated genes in boys, but not in girls, has been revealed. A linear dose-dependent relationship between in utero arsenic exposure levels and methylation at individual CpG loci in white cord blood cells was reported [28]. In both maternal and fetal leukocytes, exposure to high arsenic levels was positively associated with LINE-1 methylation levels and, to a lesser degree, with methylation of CpG sites within a promoter region of the tumor suppressor gene p16 [29]. Effects of prenatal arsenic exposure on DNA methylation levels in cord blood of newborns were found to be exposure-dependent; indeed, arsenic levels were shown to be associated with altered DNA methylation across the genome. This association, however, was largely attenuated after adjusting for leukocyte distribution [30].

Prenatal arsenic exposure may be associated with global methylation profiles in a sex-specific manner. Such differences between sexes were observed, e.g. in the study by Pilsner et al. [31] where impacts of in utero exposure to arsenic on global DNA methylation patterns were assessed either by genome-wide assays [methyl incorporation and LUMinometric Methylation Assay (LUMA)] or by repetitive element assays (Alu and LINE-1). In this study, associations between prenatal arsenic exposure and methylation levels evaluated by LUMA and also methylation of Alu and LINE-1 repetitive elements were found to be negative among female newborns but positive among male newborns [31]. Significant associations between intrauterine arsenic exposure and DNA methylation levels have been reported in a Taiwanese population [32]. Among all identified CpGs, about 60% have been shown to be positively related to arsenic exposure. Following functional annotation analysis of these 5′-C-phosphate-G-3′, 17 pathways were identified including those associated with risk for T2D and CVD later in life. Consistent associations have been also observed in other independent cohorts [32].

The genome-wide impact of prenatal arsenic exposure on the newborn gene expression profiles was evaluated by microarray in cord blood cells [33]. In comparing transcripts from 21 newborns whose mothers were exposed to arsenic during pregnancy versus 11 newborns whose mothers were unexposed, about 450 differentially expressed genes were identified. In a network analysis of arsenic-modulated transcripts, activation of molecular networks related to stress, apoptosis, metal exposure and inflammation was demonstrated. Arsenic concentrations in maternal blood positively correlated to the expression of the soluble fms-like tyrosine kinase-1 (sFLT1) gene, playing an important role in the inhibition of placental angiogenesis and associated growth retardation, as well as several genes associated with DNA methylation and oxidative stress [34]. Moreover, genes that demonstrated most pronounced differences in DNA methylation and expression levels in newborn cord blood after prenatal exposure to arsenic were found to be enriched for binding sites of the early growth response (EGR) and CCCTC-binding transcription factors [35]. Evidence is also obtained that in utero exposure to arsenic can affect DNA methylation at the p53 promoter region, thereby potentially promoting carcinogenesis [36].

In discussing the potential role of epigenetic mechanisms in mediating developmental programming effects of TMs, an important point is that prenatal arsenic exposure was shown to be able to cause persisting epigenetic modifications in affected offspring. In Bangladesh, prenatal maternal exposure to arsenic has been positively associated with concentrations of insulin-like growth factor-binding protein 3 (IGFBP3) in 9-year-old children [37]. It has been suggested that these modifications can be epigenetically mediated. Specifically, altered methylation of 12 CpG sites mediated the association between prenatal arsenic exposure and IGFBP3 levels in these children [37].

**Lead**

Lead is a TM known to strongly affect human beings. Fetuses and young children were found to be especially susceptible to its neurotoxic effects because this metal is characterized by high gastrointestinal absorption and is able to penetrate the blood–brain boundaries [38].

| TM Country | Age at detection | Tissue/cells | Gene/element | Epigenetic outcome | Ref. |
|-------------|------------------|-------------|--------------|-------------------|------|
| USA (n = 306) | At birth (n = 306), early childhood (n = 68), mid-childhood (n = 260) | Cord blood | MWAS | Lowered 5-hmC genomic content | [46] |
| USA (n = 141) | At birth | Cord blood | ANGPT2 PRPF18 FOXD2 TCEACN2 | Differentially methylated regions | [47] |
| USA (n = 192) | At birth | Placental samples | EMID2 HDHD1 | Hypomethylated loci | [48] |
| Japan (n = 67) | At birth | Cord tissue | | Increased body methylation | [49] |
| Seychelles (n = 406) | Children at 7 years of age | Saliva | GRIN2B NR3C1 | Increased methylation at CpG sites | [50] |
DNA methylation changes induced by prenatal toxic metal exposure

barrier [38]. Exposure to lead in utero has been repeatedly reported to be related to a hematopoietic toxicity and also to impaired neurological development and severe cognitive deficits in adulthood. Several studies conducted mainly in Mexican population have demonstrated a role of epigenetic mechanisms in mediating these associations [39–42]. In evaluating the impact of prenatal lead exposure on global DNA methylation levels (assessed by Alu and LINE-1 repetitive elements) in cord blood leukocytes, an inverse dose-response relationship between lead concentrations in maternal patella and LINE-1 methylation levels has been observed, whereas lead levels in maternal tibia have been found to be inversely related to Alu methylation levels [39]. An association between intrauterine exposure to lead and genome-wide changes in 5-hydroxymethylcytosine (5-hmC) profiles in CpG islands in cord blood cells was also reported [40]. Moreover, trimester-specific prenatal lead exposure–associated DMRs was found in umbilical cord blood leukocytes in 15 gene pathways related to a nodal signaling and neurological system processes and also involved in immunoglobulin binding, transmembrane receptor activity, detection of chemical stimulus, sensory perception and smell, and olfactory receptor activity [41]. In the United States, strong inverse associations with prenatal lead exposure were observed for methylation levels of CpGs in genes encoding Dynemin heavy Chain Domain 1 (DNHD1), known to be highly expressed in human brain, as well as in genes encoding C-Type Lectin Domain Family 11, Member A (CLEC11A), a growth factor for primitive hematopoietic progenitor cells [42]. These epigenetic alterations have been found to be more pronounced in female than in male neonates. More recently, however, no association between prenatal lead exposure and cord blood methylation was observed [43]. Such differences in results could be likely attributed to differences in protocol, cohort characteristics, exposure levels, timing of exposure measurement, methods used for statistical analysis and so on.

Mercury

Prenatal exposure to another TM, mercury, was repeatedly shown to be associated with severe neurodevelopmental outcomes and with a lower cognitive performance in childhood [44]. Several studies showed that this association is mediated by epigenetic mechanisms. Prenatal mercury exposure has been associated with differential DNA methylation, mostly in CpG islands, in umbilical cord blood [45]. According to the authors, these changes were suggestive of altered immune profiles in exposed infants. Mercury-induced changes in methylation levels of Paraoxonase 1 (PON1) gene, which predict lower cognitive test scores, were shown to be able to persist into early childhood [44]. In addition, mercury exposure in utero has been related to lower global 5-methylcytosine content and respective increase in the ratio of 5-methylcytosine to 5-hmC in cord blood. These associations have been shown to persist into early but not into middle childhood [46]. Prenatal concentrations of mercury and methylated form of mercury (methylmercury) were both associated with changes in DNA methylation at several important genes, including Transcription Elongation Factor A N-Terminal and Central Domain Containing 2 (TCEANC2) gene, in newborns [47]. Associations between concentrations of infant toenail mercury, disturbed placental DNA methylation, e.g. in EMID2 gene, and high-risk neurodevelopmental profiles in newborns have been also reported [48]. Association between mercury concentration in cord serum and DNA methylation in cord tissues was found to be sex-specific, at least for several genes. For example, in a recent study by Nishizawa-Jotaki et al. [49], methylated locus located in the intron of haloacid dehalogenase-like hydrolase domain-containing protein 1 (HDHD1) gene, encoding a binding site for the zinc finger protein CCCTC-binding factor, was shown to be positively correlated with mercury concentrations in cord serum in male, but not in female newborns. In another recent study, prenatal exposure to higher levels of methylmercury from maternal fish consumption resulted in epigenetic changes in offspring which have persisted at least until 7 years of age [50]. These changes were observed for certain nervous system–associated genes, including those encoding glutamate receptor subunit NR2B (GRIN2B) and glucocorticoid receptor (NR3C1). More specifically, exposure to higher levels of methylmercury in utero was associated with elevated methylation in particular CpG sites (located mostly in transcription factor binding sites) of these genes [50].

Conclusions and Perspectives

In conclusion, research evidence provided in this Perspective paper seems to be sufficient to conclude that prenatal exposure to environmental xenobiotics such as TMs can be an important factor contributing to developmental epigenetic programming of health status and disease profiles in modern human populations. Studies aimed at the identification of epigenetic pathways involved in these processes seem all the more important given the fact that current living conditions are very different from those constituted environmental context of human evolutionary history. In present-day environmental conditions, exposure to man-made environmental pollutants such as high-dose TMs is undoubtedly a factor significantly influencing genetically determined pathways of epigenetic regulation and thereby causing various pathological outcomes. Exposure to TMs in utero can be especially hazardous. This is because an organism is most sensitive to stressful events throughout prenatal and early postnatal periods [3]. Moreover, developmentally induced epigenetic modifications can persist long even after a transient environmental signal has disappeared, thereby enhancing the risk for future disorders, sometimes even in subsequent generations (due to the mechanism of transgenerational epigenetic inheritance) [51–55].

Currently, an exploration of the role of epigenetic processes in mediating long-term health effects of developmental exposure to TMs is in the focus of various research activities [56–58]. Multiple genes have been identified to date, which are involved in these associations. While significant progress has been made over recent years in this research field, many issues still remain to be addressed. Most evidence for epigenetic effects of prenatal TM exposures was obtained from newborn cord blood samples and, more rarely, from placental tissues [24, 48]. Long-term persistence of such effects beyond birth was reported only in few studies, and evidence that epigenetic changes represent a mechanism linking developmental toxic exposure to adverse health outcomes later in life is also limited to few studies that performed causal mediation analysis. The causality cannot be definitely inferred from epidemiological studies; therefore, further experimental studies are needed to elucidate the mechanistic basis for these effects.

In discussing mechanisms underlying effects of developmental exposures to TMs on DNA methylation, it is usually assumed that these effects can be mediated by a direct action of environmental chemicals on the enzyme families such as DNMT and ten-eleven translocation protein (enzyme families responsible for the DNA methylation and demethylation, respectively) [57]. Moreover, prenatal exposures to TMs can affect the availability of S-adenosylmethionine (the substrate required for DNA methylation). In addition, according to the transcription factor
occupancy theory, it is suggested that dysregulation of transcription factors by toxic environmental exposures can affect site-specific patterns of DNA methylation, because the presence or absence of transcription factors on DNA allows or denies access to the DNA methylation machinery. More specifically, binding of certain transcription factors could inhibit DNMT from accessing DNA for methylation of particular genes, thereby causing gene-specific hypomethylation, while a lack of transcription factor binding might allow DNMT access to certain genomic locations, thereby leading to gene-specific hypermethylation [57].

One potential challenge is that specific epigenetic patterns are characteristic for certain cell types and also for particular cellular signaling pathways. Therefore, the focus of further research activity probably should have been shifted from the research of single candidate genes to investigating candidate gene pathways known to be epigenetically labile and react in a specific manner in response to specific environmental triggers. Characterization of these gene pathways by performing studies integrating all the potentially hazardous TM exposures in utero, epigenetic modifications induced by these exposures and resulting adult health outcomes would provide an opportunity to further elucidate epigenetic mechanisms mediating these associations. An important issue in studying long-term epigenetic changes is that such changes can significantly vary in sign and magnitude in various adult body tissues [59]. This is an essential challenge, given the difficulty of obtaining biological samples in human research. Today, only samples from peripheral blood or buccal swabs were used in such studies. A study of postmortem samples could provide such an opportunity [60]. However, to our knowledge, such studies have not been carried out to date. Thus, performing studies in animal models is the only reasonable alternative now in further elucidating such inter-tissue differences. Such an approach, in turn, raises the question on the specificity of these pathways across species and, more specifically, on similarities or differences between such pathways in experimental animals and humans. In addition, the process of developmental programming can be largely influenced by interplays between environmental factors operating in fetal and early postnatal life [61, 62]. Furthermore, since epigenome remains sufficiently labile and capable of responding to environmental factors during adulthood as well (although to a lesser extent than during early development) [3], the potential role of stressful events in adult life also needs to be taken into account. Given the complexity of potentially interacting factors influencing these processes, choosing the right study design is an important issue. In particular, cross-sectional approach, which is most commonly used in epigenetic epidemiology now, allows only limited inferences about causal relationships between early-life risk factors and later health outcomes. Therefore, longitudinal cohort design will be likely the approach, which is most commonly used in epigenetic epidemiology studies, including those aimed at appraising long-term health outcomes of early-life exposures to TMs.

The importance of these studies lies in the fact that, since developmental epigenetic modifications are potentially reversible [3], a better understanding of mechanisms contributed to effects of adverse in utero exposures may provide an opportunity for developing novel therapeutic approaches aimed at correction of developmentally disrupted epigenetic profiles. One promising direction in this area is the development of new drug classes (so-called “epigenetic drugs”) [63]. Such drugs, include, among others, pharmacological agents targeted at enzymes involved in epigenetic regulation, such as inhibitors of DNMTs and histone deacetylases [64], and these pharmaceuticals are under active investigation and clinical implementation now.

Data Availability
Data might be available under request to corresponding author.

Funding
No funds were received from governmental or private agencies to conduct this study.

Conflict of interest statement. None declared.

References
1. Mitchell E, Walker R. Global ageing: successes, challenges and opportunities. Br J Hosp Med (Lond) 2020;81:1–9.
2. Felix JF, Cecil CAM. Population DNA methylation studies in the Developmental Origins of Health and Disease (DOHaD) framework. J Dev Orig Health Dis 2019;10:306–13.
3. Hochberg Z, Feil R, Constancia M et al. Child health, developmental plasticity, and epigenetic programming. Endocr Rev 2011;32:159–224.
4. Nilsson EE, Maamar MB, Skinner MK. Environmentally induced epigenetic transgenerational inheritance and the Weismann Barrier: the dawn of Neo-Lamarckian theory. J Dev Biol 2020;8:28.
5. Linnér A, Almgren M. Epigenetic programming—the important first 1000 days. Acta Paediatr 2020;109:443–52.
6. Vaiserman A, Koliada A, Lushchak O. Developmental programming of aging trajectory. Ageing Res Rev 2018;47:105–22.
7. Briffa J, Sinagra E, Blundell R. Heavy metal pollution in the environment and their toxicological effects on humans. Heliyon 2020;6.e04691.
8. Renu K, Chakraborty R, Myakala H et al. Molecular mechanism of heavy metals (lead, chromium, arsenic, mercury, nickel and cadmium) - induced hepatotoxicity - a review. Chemosphere 2021;271:129735.
9. Lacagnina S. The Developmental Origins of Health and Disease (DOHaD). Am J Lifestyle Med 2019;14:47–50.
10. Martinez-Zamudio R, Ha HC. Environmental epigenetics in metal exposure. Epigenetics 2011;6:820–7.
11. Fragu D, Fragu A, Kouidou S et al. Epigenetic mechanisms in metal toxicity. Toxicol Mech Methods 2011;21:343–52.
12. Cheng TF, Choudhuri S, Mulshoon-Jacobs K. Epigenetic targets of some toxicologically relevant metals: a review of the literature. J Appl Toxicol 2012;32:643–53.
13. Mohideen K, Muhammad R, Davey CA. Perturbations in nucleosome structure from heavy metal association. Nucleic Acids Res 2010;38:6301–11.
14. Benbrahim-Tallaa L, Waterland RA, Dill AL et al. Tumor suppressor gene inactivation during cadmium-induced malignant transformation of human prostate cells correlates with overexpression of de novo DNA methyltransferase. Environ Health Perspect 2007;115:1454–9.
15. Reichard JF, Schnekenburger M, Puga A. Long term low-dose arsenic exposure induces loss of DNA methylation. Biochem Biophys Res Commun 2007;352:188–92.
16. Jan AT, Azam M, Siddiqui K et al. Heavy metals and human health: mechanistic insight into toxicity and counter defense system of antioxidants. Int J Mol Sci 2015;16:29592–630.
17. Jaishankar M, Tseten T, Anbalagan N et al. Toxicity, mechanism and health effects of some heavy metals. Interdiscip Toxicol 2014;7:60–72.
36. Gundacker C, Hengstschläger M. The role of the placenta in fetal exposure to heavy metals. Wien Med Wochenschr 2012;162:201–6.

37. Bitto A, Pizzino G, Irrera N et al. Epigenetic modifications due to heavy metals exposure in children living in polluted areas. Curr Genomics 2014;15:464–8.

38. Young JL, Cai L. Implications for prenatal cadmium exposure and adverse health outcomes in adulthood. Toxicol Appl Pharmacol 2020;403:115161.

39. Sanders AP, Smeester L, Rojas D et al. Cadmium exposure and the epigenome: exposure-associated patterns of DNA methylation in leukocytes from mother-baby pairs. Epigenetics 2014;9:212–21.

40. Everson TM, Maroble C, Deyssenroth MA et al. Placental expression of imprinted genes, overall and in sex-specific patterns, associated with placental cadmium concentrations and birth size. Environ Health Perspect 2019;127:57005.

41. Vidal AC, Semenova V, Darrah T et al. Maternal cadmium, iron and zinc levels, DNA methylation and birth weight. BMC Pharmacol Toxicol 2015;16:20.

42. Young JL, Cai L, States JC. Impact of prenatal arsenic exposure on chronic adult diseases. Syst Biol Reprod Med 2018;64:469–83.

43. Broberg K, Ahmed S, Engström K et al. Arsenic exposure in early pregnancy alters genome-wide DNA methylation in cord blood, particularly in boys. J Dev Orig Health Dis 2014;5:288–98.

44. Koestler DC, Avissar-Whiting M, Houseman EA et al. Differential DNA methylation in umbilical cord blood of infants exposed to low levels of arsenic in utero. Environ Health Perspect 2013;121:971–7.

45. Kile ML, Baccarelli A, Hoffman E et al. Prenatal arsenic exposure and DNA methylation in maternal and umbilical cord blood leukocytes. Environ Health Perspect 2012;120:1061–6.

46. Kile ML, Houseman EA, Baccarelli AA et al. Effect of prenatal arsenic exposure on DNA methylation and leukocyte subpopulations in cord blood. Epigenetics 2014;9:774–82.

47. Pilsner JR, Hall MN, Liu X et al. Influence of prenatal arsenic exposure and newborn sex on global methylation of cord blood DNA. PLoS One 2012;7:e37147.

48. Kaushal A, Zhang H, Karmaus WJ et al. Genome-wide DNA methylation at birth in relation to in utero arsenic exposure and the associated health in later life. Environ Health 2017;16:50.

49. Fry RC, Navasumrit P, Valiathan C et al. Activation of inflammation/NF–kappaB signaling in infants born to arsenic-exposed mothers. PLoS Genet 2007;3:e207.

50. Remy S, Govarts E, Bruckers L et al. Expression of the sFlt1 gene in cord blood cells is associated to maternal arsenic exposure and decreased birth weight. PLoS One 2014;9:e92677.

51. Rojas D, Rager JE, Smeester L et al. Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci 2015;143:97–106.

52. Intarasunanont P, Navasumrit P, Waraprasis S et al. Effects of arsenic exposure on DNA methylation in cord blood samples from newborn babies and in a human lymphoblast cell line. Environ Health 2012;11:31.

53. Gliga AR, Engström K, Kippler M et al. Prenatal arsenic exposure is associated with increased plasma IGFBP3 concentrations in 9-year-old children partly via changes in DNA methylation. Arch Toxicol 2018;92:2487–500.

54. Flora G, Gupta D, Tiwari A. Toxicity of lead: a review with recent updates. Interdiscip Toxicol 2012;5:47–58.

55. Pilsner JR, Hu H, Ettinger A et al. Influence of prenatal lead exposure on genomic methylation of cord blood DNA. Environ Health Perspect 2009;117:1466–71.

56. Sen A, Cingolani P, Senut MC et al. Lead exposure induces changes in 5-hydroxymethylcytosine clusters in CpG islands in human embryonic stem cells and umbilical cord blood. Epigenetics 2015;10:607–21.

57. Rygiel CA, Dolinoy DC, Perng W et al. Trimester-specific associations of prenatal lead exposure with infant cord blood DNA methylation at birth. Epigenet Insights 2020;13:2516865720986669.

58. Wu S, Hivert MF, Cardenas A et al. Exposure to low levels of lead in utero and umbilical cord DNA methylation in project viva: an epigenome-wide association study. Environ Health Perspect 2017;125:087019.

59. Heiss JA, Téllez-Rojo MM, Estrada-Gutiérrez G et al. Prenatal lead exposure and cord blood DNA methylation in PROGRESS: an epigenome-wide association study. Environ Epigenet 2020;6:dva014.

60. Cardenas A, Rifas-Shiman SL, Agha G et al. Persistent DNA methylation changes associated with prenatal mercury exposure and cognitive performance during childhood. Sci Rep 2017;7:288.

61. Cardenas A, Koestler DC, Houseman EA et al. Differential DNA methylation in umbilical cord blood of infants exposed to mercury and arsenic in utero. Epigenetics 2015;10:508–15.

62. Cardenas A, Rifas-Shiman SL, Godderis L et al. Prenatal exposure to mercury: associations with global DNA methylation and hydroxymethylation in cord blood and in childhood. Environ Health Perspect 2017;125:087022.

63. Bakulski KM, Lee H, Feinberg II et al. Prenatal mercury concentration is associated with changes in DNA methylation at TCEANC2 in newborns. Int J Epidemiol 2015;44:1249–62.

64. Maccani JZ, Koestler DC, Lester B et al. Placental DNA methylation related to both infant toenail mercury and adverse neurobehavioral outcomes. Environ Health Perspect 2015;123:723–9.

65. Nishizawa-Jotaki S, Sakurai K, Eguchi A et al. Association between mercury in cord serum and sex–specific DNA methylation in cord tissues. J Dev Orig Health Dis 2021;12:124–31.

66. Cediel Ulloa A, Giga A, Love TM et al. Prenatal methylmercury exposure and DNA methylation in seven-year-old children in the Seychelles Child Development Study. Environ Int 2021;147:106321.

67. Vaiserman AM, Koliada AK, Jirtle RL. Non-genomic transmission of longevity between generations: potential mechanisms and evidence across species. Epigenetics Chromatin 2017;10:38.

68. Hanson MA, Skinner MK. Developmental origins of epigenetic transgenerational inheritance. Environ Epigenet 2016;2:dvw002.

69. Nilsson EE, Sadler-Riggelman I, Skinner MK. Environmentally induced epigenetic transgenerational inheritance of disease. Environ Epigenet 2018;4:dvy016.
54. Nilsson EE, Maamar MB, Skinner MK. Environmentally induced epigenetic transgenerational inheritance and the Weismann barrier: the dawn of neo-Lamarckian theory. *J Dev Biol* 2020;8:28.
55. Bošković A, Rando OJ. Transgenerational epigenetic inheritance. *Annu Rev Genet* 2018;52:21–41.
56. Barouki R, Melén E, Herceg Z *et al.* Epigenetics as a mechanism linking developmental exposures to long-term toxicity. *Environ Int* 2018;114:77–86.
57. Martin EM, Fry RC. Environmental influences on the epigenome: exposure-associated DNA methylation in human populations. *Annu Rev Public Health* 2018;39:309–33.
58. Chung FF, Herceg Z. The promises and challenges of toxic-epigenomics: environmental chemicals and their impacts on the epigenome. *Environ Health Perspect* 2020;128:15001.
59. Murphy SK, Huang Z, Hoyo C. Differentially methylated regions of imprinted genes in prenatal, perinatal and postnatal human tissues. *PLoS One* 2012;7:e40924.
60. Bakulski KM, Fallin MD. Epigenetic epidemiology: promises for public health research. *Environ Mol Mutagen* 2014;55:171–83.
61. Vaiserman AM. Birth weight predicts aging trajectory: a hypothesis. *Mech Ageing Dev* 2018;173:61–70.
62. Vaiserman A. Developmental tuning of epigenetic clock. *Front Genet* 2018;9:584.
63. Vaiserman AM, Pasyukova EG. Epigenetic drugs: a novel anti-aging strategy? *Front Genet* 2012;3:224.
64. Pasyukova EG, Symonenko AV, Rybina OY *et al.* Epigenetic enzymes: a role in aging and prospects for pharmacological targeting. *Ageing Res Rev* 2021;67:101312.